Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ: IXHL )

1.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.680
Bid (Size) 1.600 (57)
Ask (Size) 2.000 (39)
Prev. Close 1.680
Today's Range 1.680 - 1.680
52wk Range 0.8000 - 12.68
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Incannex Healthcare secures $60M in financing from Arena Investors to support clinical trials for cannabinoid and psychedelic therapies. 
Via Benzinga
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
New York, New York--(Newsfile Corp. - September 9, 2024) - Quantum Research Group, LLC just published the results of a... 
Via Newsfile

Performance

YTD
-61.82%
-61.82%
1 Month
-2.89%
-2.89%
3 Month
-42.07%
-42.07%
6 Month
-50.15%
-50.15%
1 Year
+50.00%
+50.00%

More News

Read More
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
FDA Experts Weigh In On Incannex's CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder
Via Benzinga
Exposures Product Safety
Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD)
Via Newsfile
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psychedelic-Assisted Therapy Advancements Create A New Horizon For Mental Health In Colorado
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
Via Talk Markets
Exposures Product Safety
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
Via Talk Markets
Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety
Via Benzinga
What's Going On With Incannex Stock?
Via Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
How I Swing Trade Via Strength With Recent Examples
Via Talk Markets
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Via Talk Markets
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
Via Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.